hospital sector represents the most dynamic and active sector of the antibiotic
and antifungal markets. In 2007, leading hospital antibiotic and antifungal
brands generated more than $3.8 billion in sales in the United States. In contrast to outpatient markets that have become increasingly generic with few
antibiotics in development, a range of novel agents, including next generation
glycopeptides, cephalosporins, and anti-Clostridium difficile
are in late stages of development targeting infections in the hospital sector. Moreover,
reimbursement in the hospital setting is poised to undergo significant changes
in light of Medicare’s Hospital-Acquired Conditions (HAC) Initiative, effective
October 1, 2008, which states that the Centers for Medicare & Medicaid
Services will no longer pay hospitals at a higher rate for the additional costs
of treating any of eight conditions commonly acquired during a patient’s hospital
Resources’ Physician&PayerForum report "Hospital
Anti-Infectives: Insights on the Impact of Medicare Reforms, Formulary
Inclusion, and Uptake of Novel Antibiotics and Antifungals" explores,
based on the view of prescribers and pharmacy and
therapeutics (P&T) committee members, how new anti-infective therapies
will shape the future of the antibiotic and antifungal treatment practice in
the hospital setting and how the Medicare HAC Initiative will change
surveyed 50 infectious disease (ID) specialists, 51 critical care (CC) specialists,
and an additional 22 ID specialists who sit on their hospital’s P&T
committee, and compared their responses to assess similarities and differences.
This survey enabled Decision Resources to accomplish the following:
- Assess and compare the concerns of ID specialists, CC specialists, and P&T
committee members regarding key hospital pathogens with respect to current and
- Evaluate physicians’
usage patterns of leading antibiotic and antifungal brands and their perceptions of emerging antibacterials and
- Evaluate the impact of Medicare’s HAC Initiative on prescribing practices and
infection control/prevention measures.
- Measure the extent to which ID specialists and CC specialists plan to use novel
anti-MRSA agents such as Johnson & Johnson/Basilea
Pharmaceutica’s ceftobiprole, Theravance/Astellas's telavancin, Targanta’s oritavancin, and Arpida’s iclaprim
in their clinical practice.
- Explore how hospital P&T committee members and physicians perceive the
echinocandins (e.g., Merck’s Cancidas, Pfizer’s Eraxis, Astellas’s Mycamine) and azoles such as
Pfizer’s Vfend and Schering-Plough’s Noxafil.
- Understand the drivers of hospital formulary inclusion and offer insight on how
companies need to differentiate their brands to gain favorable placement.
- Evaluate the impact of the future formulary and restriction status of emerging
anti-infectives on their uptake in the highly competitive hospital